Theranexus SA (FR:ALTHX) has released an update.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Theranexus reports a slight increase in cash reserves to €1.9 million as of September 30, 2024, aided by a significant research tax credit. The company remains focused on advancing its treatments for rare neurological diseases, aiming to register its liquid miglustat formulation in Europe and initiate a phase 3 trial for Batten disease.
For further insights into FR:ALTHX stock, check out TipRanks’ Stock Analysis page.